| 2024-10-29 | +12.7% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2025-02-10 | -11.3% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2025-07-29 | +10.9% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2022-02-08 | -9.2% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2026-02-10 | -9.1% | earnings | Seeking Alpha | Incyte outlines 10–13% revenue growth for 2026 amid robust pipeline expansion and new product launches |
| 2026-02-10 | -9.1% | earnings | Seeking Alpha | Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript |
| 2026-02-10 | -9.1% | earnings | Seeking Alpha | Incyte falls as Q4 results, 2026 revenue guidance disappoint |
| 2026-02-10 | -9.1% | earnings | Seeking Alpha | Incyte Corporation 2025 Q4 - Results - Earnings Call Presentation |
| 2026-02-10 | -9.1% | earnings | Seeking Alpha | Incyte reports mixed Q4 results; initiates FY26 outlook |
| 2026-02-10 | -9.1% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2026-02-10 | -9.1% | news | Yahoo Finance | Why Incyte (INCY) Stock Is Nosediving - Yahoo Finance |
| 2026-02-10 | -9.1% | earnings | Finviz | Incyte (NASDAQ:INCY) Surprises With Q4 CY2025 Sales - Finviz |
| 2026-02-10 | -9.1% | news | MarketWatch | Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch |
| 2026-02-10 | -9.1% | earnings | ChartMill | Incyte Corp. (NASDAQ:INCY) Reports Mixed Q4 2025 Results with Revenue Beat and EPS Miss - ChartMill |
| 2026-01-06 | +8.4% | analyst | Seeking Alpha | Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins |
| 2026-01-06 | +8.4% | news | Seeking Alpha | Top 10 Stocks For 2026 |
| 2026-01-06 | +8.4% | analyst | Seeking Alpha | Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins (NASDAQ:INCY) - Seeking Alpha |
| 2026-02-09 | -7.9% | analyst | Seeking Alpha | From Gold to Chips: Large-Cap names with the most days at bullish Quant ratings |
| 2023-05-02 | -7.9% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2022-08-02 | -7.2% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2024-05-13 | +7.0% | legal | SEC EDGAR | INCY 8-K: 1.01, 7.01 (SEC Filing) |
| 2025-12-08 | -6.8% | analyst | MarketWatch | Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch |
| 2022-11-01 | +6.7% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2024-07-30 | -6.2% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2025-12-06 | -5.4% | news | Seeking Alpha | Incyte: Buy At This Inflection Point (NASDAQ:INCY) - Seeking Alpha |
| 2025-11-04 | +4.9% | news | Yahoo Finance | Incyte (INCY) Extends Climb, Hits New High on Bullish Coverage - Yahoo Finance |
| 2025-06-27 | -4.8% | legal | SEC EDGAR | INCY 8-K: 5.02 and (SEC Filing) |
| 2023-02-07 | -4.8% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2023-08-01 | +4.7% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2021-11-02 | -4.7% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2025-04-29 | +4.6% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2025-09-11 | -4.4% | news | Yahoo Finance | Incyte Corporation (INCY) Advances KRAS Cancer Program - Yahoo Finance |
| 2025-10-30 | +4.4% | earnings | Yahoo Finance | Incyte Corp (INCY) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance |
| 2021-05-04 | -4.4% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2026-01-05 | +3.9% | news | Seeking Alpha | Incyte marks late-stage trial win for Xencor-partnered lymphoma therapy |
| 2024-07-03 | -3.9% | legal | SEC EDGAR | INCY 8-K: 1.01 and 2.03 (SEC Filing) |
| 2025-12-12 | +3.9% | legal | SEC EDGAR | INCY 8-K: 5.02 (SEC Filing) |
| 2026-02-12 | +3.8% | analyst | FinancialContent | Do Wall Street Analysts Like Incyte Corporation Stock? - FinancialContent |
| 2026-02-06 | +3.7% | earnings | The Globe and Mail | Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards? - The Globe and Mail |
| 2022-01-14 | +3.6% | legal | SEC EDGAR | INCY 8-K: 5.02 (SEC Filing) |
| 2026-02-04 | +3.6% | earnings | Yahoo Finance | TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029 - Yahoo Finance |
| 2026-04-15 | -3.5% | news | TradingView | Do Options Traders Know Something About Incyte Stock We Don't? - TradingView |
| 2025-10-28 | -3.4% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2025-10-28 | -3.4% | earnings | Yahoo Finance | Incyte (INCY) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance |
| 2026-01-12 | -3.2% | news | Seeking Alpha | Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2026-01-22 | -3.1% | news | Seeking Alpha | What Investors Should Know Before Buying Incyte |
| 2026-01-22 | -3.1% | news | Seeking Alpha | What Investors Should Know Before Buying Incyte Stock (NASDAQ:INCY) - Seeking Alpha |
| 2026-03-25 | +3.0% | earnings | Investing.com | UBS lowers Incyte stock price target on revenue concerns to $94 - Investing.com |
| 2025-09-02 | +3.0% | news | Yahoo Finance | Incyte (INCY) Stock Is Up, What You Need To Know - Yahoo Finance |
| 2026-04-06 | -2.9% | news | DirectorsTalk Interviews | Incyte Corporation (INCY) Stock Analysis: Unpacking the 11.68% Potential Upside for Investors - DirectorsTalk Interviews |
| 2025-12-22 | -2.8% | news | Yahoo Finance | Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance |
| 2025-07-30 | -2.7% | news | Yahoo Finance | Why Incyte (INCY) is a Top Value Stock for the Long-Term - Yahoo Finance |
| 2025-10-21 | +2.7% | earnings | Yahoo Finance | Incyte's Quarterly Earnings Preview: What You Need to Know - Yahoo Finance |
| 2025-10-21 | +2.7% | news | Seeking Alpha | Incyte Stock: Strong Growth, Margin Expansion And Low Valuation (NASDAQ:INCY) - Seeking Alpha |
| 2024-04-30 | +2.6% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2022-05-03 | +2.6% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2025-05-14 | +2.6% | legal | SEC EDGAR | INCY 8-K: 8.01 (SEC Filing) |
| 2026-04-23 | -2.5% | news | MT Newswires | Incyte's Minjuvi Combination Approved in Australia for Follicular Lymphoma |
| 2026-04-23 | -2.5% | earnings | Seeking Alpha | Incyte Q1 Preview: The Growth Story Remains Intact |
| 2026-04-23 | -2.5% | earnings | Seeking Alpha | Incyte Q1 Preview: The Growth Story Remains Intact (NASDAQ:INCY) - Seeking Alpha |
| 2026-04-23 | -2.5% | news | Stock Titan | Australia clears first chemo-free option for relapsed follicular lymphoma - Stock Titan |
| 2023-10-31 | +2.5% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2026-03-11 | -2.5% | news | Seeking Alpha | Incyte Corporation (INCY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript |
| 2026-03-11 | -2.5% | news | MarketWatch | Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch |
| 2023-06-15 | +2.4% | legal | SEC EDGAR | INCY 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-03-02 | -2.3% | news | Seeking Alpha | Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript |
| 2025-11-18 | -2.3% | news | ChartMill | INCYTE CORP (NASDAQ:INCY) Presents a Compelling Case for Value Investors - ChartMill |
| 2023-05-08 | -2.3% | legal | SEC EDGAR | INCY 8-K: 8.01 (SEC Filing) |
| 2026-02-11 | +2.3% | earnings | Seeking Alpha | Incyte: Why The Market Is Overreacting To A Guidance 'Miss' |
| 2026-02-11 | +2.3% | earnings | TIKR.com | Incyte Shares Drop 8% Post-Earnings: Analysts Target $104 Amid 2026 Guidance Concerns - TIKR.com |
| 2026-02-11 | +2.3% | earnings | Seeking Alpha | Incyte: Why The Market Is Overreacting To A Guidance 'Miss' (NASDAQ:INCY) - Seeking Alpha |
| 2026-02-11 | +2.3% | earnings | FinancialContent | Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss - FinancialContent |
| 2026-02-11 | +2.3% | earnings | Finviz | INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow - Finviz |
| 2026-03-10 | -2.2% | news | Seeking Alpha | Incyte Corporation (INCY) Presents at Leerink Global Healthcare Conference 2026 Transcript |
| 2026-03-10 | -2.2% | earnings | StockStory | Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings? - StockStory |
| 2026-03-10 | -2.2% | news | MarketWatch | Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch |
| 2026-01-02 | +2.2% | news | TIKR.com | Who Owns Incyte Corporation? Top Shareholders and Recent Insider Trades - TIKR.com |
| 2025-11-13 | -2.1% | news | Yahoo Finance | Incyte (INCY): Exploring Valuation After Recent Share Price Rally and Pipeline Progress - Yahoo Finance |
| 2026-02-19 | -2.1% | news | Seeking Alpha | Incyte Remains Undervalued As Opzelura And Niktimvo Scale |
| 2026-02-19 | -2.1% | analyst | Yahoo Finance | Where is Incyte Corporation (INCY) Headed According to Analysts? - Yahoo Finance |
| 2026-01-14 | +2.0% | news | Yahoo Finance | Is Incyte (INCY) Still Attractively Priced After Its Strong 1 Year Share Price Gain? - Yahoo Finance |
| 2026-01-14 | +2.0% | news | StockStory | Why Incyte (INCY) Stock Is Trading Up Today - StockStory |
| 2026-01-14 | +2.0% | news | TradingView | Why Incyte (INCY) Stock Is Trading Up Today - TradingView |
| 2025-08-20 | +1.9% | analyst | Yahoo Finance | Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink? - Yahoo Finance |
| 2022-10-04 | -1.9% | legal | SEC EDGAR | INCY 8-K: 5.02 (SEC Filing) |
| 2021-08-03 | -1.8% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2026-03-30 | +1.7% | legal | SEC EDGAR | INCY 8-K: 5.02 (SEC Filing) |
| 2026-03-30 | +1.7% | news | Stock Titan | Incyte (INCY) Board member Susanne Schaffert to step down April 15, 2026 - Stock Titan |
| 2023-09-12 | -1.6% | legal | SEC EDGAR | INCY 8-K: 5.02 (SEC Filing) |
| 2026-04-04 | -1.6% | earnings | MarketBeat | Toth Financial Advisory Corp Acquires Shares of 12,280 Incyte Corporation $INCY - MarketBeat |
| 2026-04-12 | -1.5% | earnings | MarketBeat | Beacon Harbor Wealth Advisors Inc. Takes Position in Incyte Corporation $INCY - MarketBeat |
| 2026-04-11 | -1.5% | news | ChartMill | INCYTE CORP (NASDAQ:INCY) Presents a High-Growth Momentum Breakout Setup - ChartMill |
| 2025-11-17 | +1.5% | executive | simplywall.st | Trade Alert: Advisor to CEO & Director Of Incyte Herve Hoppenot Has Sold Stock - simplywall.st |
| 2026-04-07 | -1.5% | analyst | MarketWatch | Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch |
| 2022-04-21 | +1.5% | legal | SEC EDGAR | INCY 8-K: 5.02 (SEC Filing) |
| 2025-08-14 | +1.5% | news | simplywall.st | Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26% - simplywall.st |
| 2026-03-22 | -1.4% | news | Seeking Alpha | Incyte: An Undervalued Healthcare Gem (NASDAQ:INCY) - Seeking Alpha |
| 2026-04-22 | -1.4% | earnings | Motley Fool | Incyte (INCY) Q4 2024 Earnings Transcript |
| 2026-04-22 | -1.4% | earnings | Zacks | Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline |
| 2026-04-22 | -1.4% | earnings | MarketBeat | Incyte Corporation $INCY Stock Holdings Raised by Zurcher Kantonalbank Zurich Cantonalbank - MarketBeat |
| 2026-04-22 | -1.4% | news | Stock Titan | INCY Financials: Income Statement, Balance Sheet & Cash Flow | Incyte Corp - Stock Titan |
| 2026-04-22 | -1.4% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | Incyte (INCY) Stock Analysis | Incyte Corp Posts 8.5% EPS Miss Vs Consensus Views - Most Discussed Stocks - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-22 | -1.4% | earnings | MarketBeat | 31,459 Shares in Incyte Corporation $INCY Bought by CPC Advisors LLC - MarketBeat |
| 2026-04-22 | -1.4% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | Incyte (INCY) Stock Analysis | Incyte Corp Posts 8.5% EPS Miss Vs Consensus Views - Acquisition - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-04-22 | -1.4% | earnings | Xã Châu Thành | Incyte (INCY) Stock Analysis | Incyte Corp Posts 8.5% EPS Miss Vs Consensus Views - Most Discussed Stocks - Xã Châu Thành |
| 2026-01-30 | +1.4% | news | Seeking Alpha | Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication |
| 2026-03-26 | +1.4% | news | Seeking Alpha | Top Quant rated undervalued large-cap stocks with high-growth grades |
| 2026-03-26 | +1.4% | legal | SEC EDGAR | INCY 8-K: 5.02 and (SEC Filing) |
| 2025-06-11 | -1.3% | legal | SEC EDGAR | INCY 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-02-03 | +1.3% | legal | Seeking Alpha | Prelude climbs as FDA clears study for Incyte-partnered cancer candidate |
| 2026-02-03 | +1.3% | analyst | Yahoo Finance | Analysts Differ in Opinion on Jakafi Drug Maker Incyte (INCY) - Yahoo Finance |
| 2026-02-03 | +1.3% | analyst | Finviz | Analysts Differ in Opinion on Jakafi Drug Maker Incyte (INCY) - Finviz |
| 2026-02-03 | +1.3% | earnings | Finviz | Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth - Finviz |
| 2025-11-06 | +1.2% | news | Investing.com | Incyte EVP Denton sells $60,613 in stock - Investing.com |
| 2021-09-28 | +1.0% | legal | SEC EDGAR | INCY 8-K: 5.02 (SEC Filing) |
| 2026-03-23 | -0.9% | news | Seeking Alpha | Incyte: An Undervalued Healthcare Gem |
| 2025-10-26 | +0.8% | earnings | StockStory | What To Expect From Incyte’s (INCY) Q3 Earnings - StockStory |
| 2026-04-20 | -0.8% | news | Insider Monkey | Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer |
| 2026-04-20 | -0.8% | news | Yahoo Finance | Here's Why Incyte (INCY) is a Strong Value Stock - Yahoo Finance |
| 2026-04-20 | -0.8% | news | ChartMill | Incyte Corp. (NASDAQ:INCY) Presents a Compelling Value Investment Case - ChartMill |
| 2026-04-20 | -0.8% | news | Yahoo Finance | RBC Capital Lifts PT on Incyte Corporation (INCY) to $95 From $92 - Yahoo Finance |
| 2026-04-20 | -0.8% | news | DirectorsTalk Interviews | Incyte Corporation (INCY) Stock Analysis: A Promising Biotech Play with 9.76% Potential Upside - DirectorsTalk Interviews |
| 2025-10-03 | +0.7% | legal | SEC EDGAR | INCY 8-K: 5.02 (SEC Filing) |
| 2026-04-18 | -0.7% | earnings | MarketBeat | KBC Group NV Sells 157,700 Shares of Incyte Corporation $INCY - MarketBeat |
| 2026-04-16 | -0.7% | earnings | MarketBeat | Incyte Corporation $INCY Holdings Lowered by Massachusetts Financial Services Co. MA - MarketBeat |
| 2026-04-16 | -0.7% | analyst | MarketWatch | Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch |
| 2026-01-21 | +0.7% | news | Seeking Alpha | Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow |
| 2026-04-17 | +0.7% | news | Stock Titan | INCYTE (INCY) R&D president earns 27,892 performance shares in equity award - Stock Titan |
| 2026-04-17 | +0.7% | executive | Stock Titan | INCYTE (NASDAQ: INCY) CEO granted 125,000 performance-based common shares - Stock Titan |
| 2026-04-17 | +0.7% | analyst | MarketWatch | Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch |
| 2026-04-17 | +0.7% | news | Stock Titan | INCY (NASDAQ: INCY) Form 144 lists 18,667-share option exercise and prior sales - Stock Titan |
| 2026-03-09 | -0.6% | analyst | Investing.com | Stifel reiterates Incyte stock rating after FDA setback - Investing.com |
| 2024-02-13 | +0.6% | legal | SEC EDGAR | INCY 8-K: 2.02 and (SEC Filing) |
| 2026-02-20 | -0.6% | earnings | Yahoo Finance | Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales - Yahoo Finance |
| 2026-02-21 | +0.6% | news | ChartMill | Incyte Corp (NASDAQ:INCY) Presents a Compelling Value Case with Strong Fundamentals - ChartMill |
| 2025-10-16 | -0.5% | news | StockStory | Incyte (INCY) Stock Is Up, What You Need To Know - StockStory |
| 2026-04-21 | -0.5% | legal | MT Newswires | Incyte Insider Sold Shares Worth $1,801,366, According to a Recent SEC Filing |
| 2026-04-21 | -0.5% | earnings | Zacks | Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth |
| 2026-04-21 | -0.5% | news | Business Wire | Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting |
| 2026-04-21 | -0.5% | earnings | MarketBeat | Incyte (NASDAQ:INCY) Insider Sells $1,801,365.50 in Stock - MarketBeat |
| 2026-04-21 | -0.5% | earnings | MarketBeat | Assetmark Inc. Raises Holdings in Incyte Corporation $INCY - MarketBeat |
| 2026-04-21 | -0.5% | earnings | MarketBeat | AE Wealth Management LLC Purchases New Holdings in Incyte Corporation $INCY - MarketBeat |
| 2026-04-21 | -0.5% | news | Stock Titan | Incyte's lymphoma drug gets ASCO oral slot as Phase 3 data back filings - Stock Titan |
| 2026-03-16 | +0.5% | news | Seeking Alpha | Incyte Stock: Multiple Potential Catalysts In 2026 And Beyond |
| 2026-03-16 | +0.5% | news | Seeking Alpha | Incyte Stock: Multiple Potential Catalysts In 2026 And Beyond (NASDAQ:INCY) - Seeking Alpha |
| 2021-05-27 | +0.5% | legal | SEC EDGAR | INCY 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-01-09 | -0.4% | earnings | Investor's Business Daily | This Biotech Stock Eyes Fresh Entry With 522% Earnings Growth Seen - Investor's Business Daily |
| 2026-01-16 | -0.4% | news | Seeking Alpha | Incyte: Buy For The Turnaround, Stay For The Pipeline |
| 2026-01-16 | -0.4% | news | Seeking Alpha | Incyte's Pipeline Potential Signals Massive Upside For Investors |
| 2026-01-16 | -0.4% | news | Seeking Alpha | Incyte: Buy For The Turnaround, Stay For The Pipeline (NASDAQ:INCY) - Seeking Alpha |
| 2026-01-16 | -0.4% | news | Seeking Alpha | Incyte's Pipeline Potential Signals Massive Upside For Investors (NASDAQ:INCY) - Seeking Alpha |
| 2026-01-07 | -0.4% | news | ChartMill | Incyte Corp. (NASDAQ:INCY) Emerges as a Compelling Value Stock with Strong Fundamentals - ChartMill |
| 2026-01-07 | -0.4% | news | FinancialContent | Incyte (INCY) Stock Is Up, What You Need To Know - FinancialContent |
| 2026-04-08 | +0.4% | news | MarketWatch | Incyte Corp. stock rises Wednesday, still underperforms market - MarketWatch |
| 2025-01-10 | +0.3% | legal | SEC EDGAR | INCY 8-K: 5.02 (SEC Filing) |
| 2026-03-07 | +0.3% | legal | Seeking Alpha | Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant |
| 2026-03-07 | +0.3% | legal | Seeking Alpha | Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant - Seeking Alpha |
| 2026-02-18 | +0.3% | news | Seeking Alpha | Incyte Remains Undervalued As Opzelura And Niktimvo Scale (NASDAQ:INCY) - Seeking Alpha |
| 2026-04-09 | -0.3% | analyst | MarketWatch | Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch |
| 2026-03-17 | +0.3% | earnings | Seeking Alpha | Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue |
| 2026-03-17 | +0.3% | earnings | Seeking Alpha | Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue (NASDAQ:INCY) - Seeking Alpha |
| 2021-08-20 | -0.3% | legal | SEC EDGAR | INCY 8-K: 1.01 and 2.03 (SEC Filing) |
| 2026-03-18 | +0.3% | earnings | Seeking Alpha | Tracking Baker Brothers Portfolio - Q4 2025 Update |
| 2025-08-07 | +0.3% | legal | SEC EDGAR | INCY 8-K: 5.02 (SEC Filing) |
| 2026-03-06 | +0.2% | legal | SEC EDGAR | INCY 8-K: 8.01 (SEC Filing) |
| 2026-03-06 | +0.2% | news | MarketWatch | Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch |
| 2025-09-23 | +0.2% | analyst | Yahoo Finance | Is Incyte Stock Outperforming the S&P 500? - Yahoo Finance |
| 2026-02-08 | +0.1% | earnings | FinancialContent | Incyte (INCY) Q4 Earnings: What To Expect - FinancialContent |
| 2026-02-08 | +0.1% | earnings | Finviz | Incyte (INCY) Q4 Earnings: What To Expect - Finviz |
| 2026-01-15 | +0.1% | news | Seeking Alpha | Steven Cress' Top 10 Stocks For 2026 |
| 2026-04-02 | +0.0% | M&A | Seeking Alpha | Trump imposes tariffs on drugmakers who haven't signed MFN deals |
| 2026-04-02 | +0.0% | news | Stock Titan | Incyte (INCY) director Edmund Harrigan takes 269-share grant in fees - Stock Titan |
| 2026-04-02 | +0.0% | news | Stock Titan | Incyte (INCY) director takes 265-share board fee in stock - Stock Titan |
| 2026-04-02 | +0.0% | news | Stock Titan | Incyte Corp (INCY) board rep logs 421-share RSU fee grant - Stock Titan |
| 2026-04-02 | +0.0% | analyst | MarketWatch | Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch |
| 2026-04-27 | — | earnings | TradingView | Incyte Earnings: What To Look For From INCY - TradingView |
| 2026-04-25 | — | news | Simply Wall St. | Is It Too Late To Consider Incyte (INCY) After A 60% One-Year Surge? |
| 2026-04-24 | — | news | MT Newswires | Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says |
| 2026-04-24 | — | earnings | Zacks | Incyte Gears Up to Report Q1 Earnings: What Can Investors Expect? |
| 2026-04-24 | — | news | ChartMill | INCY Stock Price, Quote & Chart | INCYTE CORP (NASDAQ:INCY) - ChartMill |
| 2026-04-24 | — | earnings | TradingView | Incyte Gears Up to Report Q1 Earnings: What Can Investors Expect? - TradingView |